Skip to content

Menu

Network Sub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact

Search

Close

Enter Search Terms

Andrew J. Storaska

Andrew J. Storaska

ID: 1b83c156-2619-30fb-68c4

/

Claimed Record

/

Organization: Rothwell Figg

PTAB to Review Two Eylea® (aflibercept) Patents After Granting Mylan’s Challenges

Biosimilars Law Bulletin · December 9, 2021

Changes to the Purple Book: Progress in Transparency

Biosimilars Law Bulletin · August 2, 2021

Getting Lost in the Thicket: AbbVie Wields Its Expansive Humira® Patent Portfolio Against Alvotech’s Adalimumab Biosimilar

Biosimilars Law Bulletin · June 24, 2021

The mRNA Patent and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)

RF EMerge · May 2, 2021

The mRNA Patent and Competitive Landscape Through One Year of the COVID-19 Pandemic–Part I

RF EMerge · April 12, 2021

Previous

12...5

Next

Practice Areas

Health Care and Life Sciences

Intellectual Property

Business and Commercial

Jurisdictions

Washington, D.C.

Publishing Record

Publisher Since 2017

Total Articles 21

Most Recent December 9, 2021

Cite This Author

Andrew J. Storaska, Rothwell Figg

LexBlog Author ID:

1b83c156-2619-30fb-68c4

www.lexblog.com/author/astoraska-2

Contact

FirmRothwell Figg

Emailastoraska@rfem.com

BlogsBiosimilars Law Bulletin

LinkedInView Profile

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS

About LexBlog
The Field We Built
Library at LexBlog
Our Beliefs
Our Team
Contact LexBlog

Disclaimer
Editorial Policy
Terms of Service

Get Started
Publishing Solutions
Compass

Submit a Request
Support Center
System Status

Copyright © 2026, LexBlog, Inc. All Rights Reserved.

Law blog design & platform by LexBlog